share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度报表
美股sec公告 ·  05/15 08:35
Moomoo AI 已提取核心信息
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
临床阶段生物制药公司ZyVersa Therapeutics公布了截至2024年3月31日的季度财务业绩。该公司的净亏损为280万美元，低于去年同期的350万美元净亏损。研发费用下降了51.4％，至513,000美元，这主要是由于 IC100 的制造成本降低和工资成本的降低。一般和管理费用也减少了34.6％，至230万美元，这要归因于与PIPE股票相关的付款减少，应计奖金减少以及会计费用减少。该公司在本季度末的现金状况为200万美元。ZyVersa专注于开发治疗肾脏或炎症性疾病的药物，尚未从产品销售中获得收入。该公司的未来计划包括继续其主要候选药物VAR 200和IC 100的临床开发，以及寻求额外资金以支持正在进行的运营。
临床阶段生物制药公司ZyVersa Therapeutics公布了截至2024年3月31日的季度财务业绩。该公司的净亏损为280万美元，低于去年同期的350万美元净亏损。研发费用下降了51.4％，至513,000美元，这主要是由于 IC100 的制造成本降低和工资成本的降低。一般和管理费用也减少了34.6％，至230万美元，这要归因于与PIPE股票相关的付款减少，应计奖金减少以及会计费用减少。该公司在本季度末的现金状况为200万美元。ZyVersa专注于开发治疗肾脏或炎症性疾病的药物，尚未从产品销售中获得收入。该公司的未来计划包括继续其主要候选药物VAR 200和IC 100的临床开发，以及寻求额外资金以支持正在进行的运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息